Skip to main content
PolicySpeak
← All files
AMG

Amgen

Company · United States · EU Transparency Register 42243575237-50

4
positions filed
in the 326 files tracked
4
legislative files
of 326 tracked
1
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #186 by legislative files engaged — a count of participation, not a measure of influence.

3.7
declared lobbying FTE
self-declared
€1M+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2011
in the register since

Declares membership of

  • Amgen is a member or sponsor of the following organizations in Brussels:
  • AmCham EU - American Chamber of Commerce to the EU
  • EFPIA – European Federation of Pharmaceutical Industries and Associations
  • Eucope - European Confederation of Pharmaceutical Entrepreneurs
  • EPC - European Policy Centre
  • European Business Summit
  • ALDE

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Registered as
Amgen Inc
Head office
Thousand Oaks, California, United states
EU office
Diegem

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Amgen in PolicySpeak: request access →

Work at Amgen? so we know who speaks for it.

Follow the files Amgen engages with

One email on Tuesdays when a new position is filed on these 4 files, from Amgen or from anyone else on them. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Amgen filed 4 positions between 6 Jun 2025 and 5 Jun 2026, across 4 of the 326 legislative files tracked here, attaching a full position paper 1 time.

2025 · 3 filed2026 · 1 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 3 Oct 2025source

Amgen welcomes the Commissions efforts to undertake targeted simplification measures for the MDR and IVDR. For drug device combination products (DDC), we see three main opportunities for efficiency gains: 1) Non-integral products (intended to be used exclusively with a medicinal product): Under current legislation, integral devices (e.g., prefilled syringes) are reviewed mainly by medicines authorities with limited…

European Biotech Actfiled 6 Jun 2025PDFsource

Amgen, one of the world's leading biotechnology companies, welcomes the opportunity to share our views on the upcoming EU Biotech Act and how this can ensure Europe stays competitive globally. As a company founded in the 1980s that rapidly grew to a multinational pharmaceutical company with operations in more than 100 countries, we believe we can bring valuable experience to the table.

Biotech Act IIfiled 5 Jun 2026source

Amgen welcomes the European Commissions ambition to strengthen Europes leadership in biotechnology and biomanufacturing through the Biotech Act II. As one of the worlds leading independent biotechnology companies operating across global manufacturing and supply networks, with a strong presence in Europe, we appreciate the important steps taken under Biotech Act I to address regulatory and industrial policy…

European Innovation Actfiled 23 Sept 2025source

Amgen welcomes the European Commissions ambitions for the upcoming Innovation Act. As a global biotechnology company with a strong European presence, we are committed to advancing scientific breakthroughs and ensuring they translate into meaningful outcomes for patients.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.

Showing 5 of 132.

Is this your organization?

Everything on this page comes from Amgen’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.